Key result
In patients with chronic kidney disease, the use of allopurinol was independently associated with lower arterial stiffness, reducing pulse wave velocity by a mean of 0.63 m/s compared to non-users.
Why the study?
Is allopurinol use associated with improved arterial stiffness in patients with chronic kidney disease?
Population
422 patients with chronic kidney disease with evidence of, or at high risk of, renal disease progression…
Comparison
Regular allopurinol use vs Patients not receiving allopurinol
Design
Cross-sectional
Authors
Loading...
Should not change prescribing in CKD; leaves causal benefit open pending randomized trials.
Cross-Sectional (n=422)
Yes
Is allopurinol use associated with improved arterial stiffness in patients with chronic kidney disease?
Mean Difference: -0.63 (95% CI -1.17–-0.09)
Absolute Event Rate: 9.5% vs 10.3%
p-value: p=0.02
In patients with CKD, allopurinol use is independently associated with lower arterial stiffness, providing rationale for future randomized trials to assess its cardiovascular risk reduction potential.
Ng et al. (2014) conducted a cross-sectional in Chronic Kidney Disease (n=422). Allopurinol vs. Non-allopurinol users was evaluated on Arterial stiffness determined by carotid-femoral pulse wave velocity (PWV) (MD -0.63 m/s, 95% CI -1.17 to -0.09, p=0.02). In patients with chronic kidney disease, the use of allopurinol was independently associated with lower arterial stiffness, reducing pulse wave velocity by a mean of 0.63 m/s compared to non-users.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: